RACE-CARS - RAndomized Cluster Evaluation of Cardiac ARrest Systems
RAndomized Cluster Evaluation of Cardiac ARrest Systems
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
- Other: Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators
- Other: Systematic bystander resuscitation instruction by 911 operators
- Other: Comprehensive community training of lay people in CPR and AED use.
- Other: Optimized first responder performance including earlier use of AEDs.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- OHCA of non-traumatic etiology
- Patients who are pulseless on arrival of a first responder; or patients who become pulseless in the presence of a first responder; OR patients who have a pulse on arrival of EMS, where a successful defibrillation was previously administered by a bystander or first responder.
Exclusion Criteria:
Untreated cardiac arrests, including arrests in which resuscitation efforts are not initiated or are terminated immediately upon arrival of EMS because the patient is not a viable candidate for resuscitation due to:
- injuries incompatible with life,
- the presence of rigor mortis or lividity,
- signs of decomposition, or
- the presence of a valid DNR.
- Private EMS transport that did not involve 911 dispatch (example: interfacility transport between nursing home and hospital).
- Arrest of clear and obvious traumatic etiology
- Bystander suspected cardiac arrest, where ROSC was achieved without the need for defibrillation or first responder CPR
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention (Enhanced Standard of Care)
Mass community CPR/AED training, optimize 911 medical dispatch, improve first responder performance
|
EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch
911 operators will be able to describe how to administer CPR over the phone.
Training of lay people regarding CPR and AED use.
First responders will recognize where AEDs are located and use them appropriately
|
|
No Intervention: Control (Standard of Care)
Usual care, continuing standard quality improvement effort
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival with good neurologic outcomes as measured by a CPC score of 1 or 2 at discharge
Time Frame: up to 12months
|
Cerebral Performance Category (CPC)
|
up to 12months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent of patients who receive CPR from a bystander as measured by EMS report
Time Frame: Baseline
|
Baseline
|
|
Rate of Defibrillation before paramedics arrive as measured by bystander interview
Time Frame: Baseline
|
Baseline
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of cardiac arrest patients whose cardiac arrests are recognized by 911-dispatcher through telephone call
Time Frame: Follow-up, up to 4 years
|
Follow-up, up to 4 years
|
|
|
Percent of cardiac arrest patients with responders who receive CPR instructions by 911-dispatcher through telephone call
Time Frame: Follow-up, up to 4 years
|
Follow-up, up to 4 years
|
|
|
Survival rate as measured by medical record abstraction
Time Frame: Follow-up, up to 4 years
|
Follow-up, up to 4 years
|
|
|
Change in Neurologic disability as measured by Modified Rankin Score
Time Frame: 3 months, 12 months
|
The Modified Rankin Score is a 6 point likert scale, with 0 being "No symptoms" and 6 being "Dead"
|
3 months, 12 months
|
|
Change in Quality of life as measured by the SF-36
Time Frame: 3 months, 12 months
|
The SF-36 is Is a health-related quality-of-life questionnaire consisting of thirty six questions that measure eight health domains to assess physical and mental health.
Physical health-related domains include General Health (GH), Physical Functioning (PF), Role Physical (RP), and Body Pain (BP).
|
3 months, 12 months
|
|
Change in Quality of life as measured by the EQ-5D-5L
Time Frame: 3 months, 12 months
|
The EQ-5D-5L is Quality of Life instrument measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
|
3 months, 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Christopher Granger, MD, Duke University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pro00105633
- 5UH3HL146935-06 (U.S. NIH Grant/Contract)
- 5U24HL146938-06 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.